AzTrials
AzTrials

Metastatic Lung CancerPhase 2INTRUSIONNCT05703555

INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701

A Phase 2 study testing Tusamitamab ravtansine in people with Metastatic Lung Cancer and Metastatic Breast Cancer, run by Erasmus Medical Center at 1 site in Netherlands.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This study is a prospective, open-label, multi-cohort, exploratory phase II clinical trial in patients with either CEACAM5-positive NSQ NSCLC, ER+ breast cancer or gastric cancer. Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Tusamitamab ravtansine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteNetherlands
Study dates
16 Feb 2024to 16 Feb 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients (≥ 18y) at the time of signing the Informed Consent Form (ICF).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • Estimated life expectancy ≥ 3 months
  • Expression of CEACAM5 established by an IHC assay of ≥2+ in intensity involving at least 50% of the tumor cell population in archival tumor sample (or, if not available, a fresh biopsy sample) at a metastatic site (mandatory) including distant lymph nodes.
  • Either: Metastatic or irresectable Non-Squamous Non-Small Cell Lung Cancer without EGFR/ALK/ROS aberration, as diagnosed by histological evaluation, after chemotherapy (restricted to 1 line of platinum-based chemotherapy) and immunotherapy (not more than 1 line). These therapies may have been applied concurrent or sequential; Or: Metastatic ER+ breast cancer, pathologically confirmed. ER+ is defined as ≥1% tumor staining by IHC. Participants must be no longer eligible for hormonal therapy. Participants may have had at maximum 1 prior systemic chemotherapy line.
  • A chemotherapy line in advanced/metastatic disease is an anti-cancer regimen that contains at least 1 cytotoxic chemotherapy agent and was discontinued due to progression. If a cytotoxic chemotherapy regimen was discontinued for a reason other than disease progression then this regimen does not count as a "prior line of chemotherapy" unless this regimen was discontinued after at least 2 cycles of treatment.
Show all 10Show fewer
  • Or: Metastatic gastric cancer, pathologically confirmed, with no regular treatment options left and having received all standard of care treatments.
  • Metastatic lesion accessible for repeated biopsy and willingness to undergo sequential biopsies.
  • Lesion to be biopsied must be measurable on CT according to RECIST v1.1.
  • Ability and willingness to give written informed consent and to comply with the requirements of the study.

Who cannot join

  • Medical conditions:
  • History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
  • Symptomatic or untreated brain metastases or history of leptomeningeal disease. Participants with previously treated brain metastases may participate provided that:
  • metastases are stable for at least 4 weeks according to imaging and symptoms returned to baseline; ii. there is no evidence of new or enlarging brain metastases; iii. the participant does not require any corticosteroids to manage brain metastases within 3 weeks prior to the first dose of study intervention.
  • Recent (within 6 months) Pulmonary Embolism or other recent (within 6 months) thromboembolic event requiring anticoagulant therapy.
  • Ascites requiring palliative intervention such as repeated drainage.
Show all 47Show fewer
  • Prior toxicity incurred as a result of previous anti-cancer therapy (radiation therapy, chemotherapy, or surgery) that have not resolved to ≤ grade 2 according to NCI-CTCAE version 5.0 [Appendix 3] except ocular toxicity, this should be grade 0 at baseline, without the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy.
  • Major surgical procedure (including open biopsy and excluding central line intravenous catheter) within 28 days prior to Cycle 1 Day 1, or anticipation of the need for major surgery during the course of the study treatment.
  • History of human immunodeficiency virus (HIV) antibody positive or use of antiretroviral therapy. No HIV testing is required unless mandated by local health authority.
  • Medical conditions requiring concomitant administration of strong CYP3A inhibitor or inducer unless it can be discontinued at least 2 weeks before the first administration of study intervention and discontinued for the duration of the study intervention.
  • Unable or unwilling to stop the use of (herbal) supplements which can strongly induce or inhibit CYP3A, including grapefruit containing food or juice or St. John's Wort from 2 weeks before the first Tusamitamab ravtansine administration up to the last Tusamitamab ravtansine administration.
  • Medical condition requiring concomitant administration of medication with a narrow therapeutic window that is metabolized by cytochrome P450 (CYP450) from 2 weeks before the first Tusamitamab ravtansine administration up to the last Tusamitamab ravtansine administration. See also section 5.2.
  • Specific Tusamitamab ravtansine (SAR408701) related conditions:
  • Less than 4 weeks or less than 5 times the half-life, whichever is shorter, since the last treatment of chemotherapy, biological therapy, immunotherapy or systemic radiotherapy (except palliative radiation delivered to <20% of bone marrow), before Cycle 1 Day 1.
  • Current or recent (within 4 weeks prior to Cycle 1 Day 1) treatment with another Investigational Product or participation in another investigational interventional study.
  • Any prior therapy targeting CEACAM5.
  • Prior maytansinoid DM4 treatment (ADC).
  • Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy.
  • Use of contact lenses: Participants using contact lenses who are not willing to stop wearing them for the duration of the study intervention are excluded.
  • Unresolved grade ≥0 ocular symptoms according to NCI-CTCAE version 5.0 [Appendix 3].
  • Unresolved grade ≥2 motor or sensory neuropathy symptoms according to NCI-CTCAE version 5.0 [Appendix 3].
  • Known hypersensitivity to any of the Investigational Product's excipients.
  • Concurrent treatment with any other anti-cancer therapy.
  • Previous enrollment in this study or current participation in any other clinical study involving an investigational study treatment or any other type of medical research.
  • Diagnostic assessments:
  • Inadequate bone marrow function, as defined by any of the following:
  • Absolute Neutrophil Count (ANC) < 1.5 x 109/L.
  • Platelet count < 100 x 109/L.
  • Hemoglobin < 6.0 mmol/L (<9.6 g/dL).
  • No blood and blood product transfusion or growth factors within two weeks prior to Cycle 1 Day 1.
  • Inadequate liver function, as defined by any of the following:
  • Serum (total) bilirubin > 1.5 x the Upper Limit of Normal (ULN) for the institution if no liver metastases (> 2 x ULN in patients with liver metastases).
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (AP) > 2.5 x ULN if no liver metastases (> 5x ULN in participants with liver metastases and for participants with bone metastases AP ≤ 5 ULN is allowed).
  • Hepatitis B surface antigen or hepatitis C positivity in combination with abnormal liver function tests if it is indicated to be determined by the Investigator.
  • Inadequate renal function, as defined by any of the following:
  • Serum creatinine > 1.5 x ULN.
  • Estimated Glomerular Filtration Rate of < 50 mL/min/1.73m2 as estimated using CKD-EPI formula.
  • Serum albumin value < 25 g/L
  • Others:
  • Patients who are pregnant or breastfeeding. Female participants of childbearing potential must have a negative serum pregnancy test before the first dose of study intervention. Serum pregnancy tests will be carried out every 4 weeks during study treatment.
  • Absence of effective means of contraception on Cycle 1 Day 1 in female participants of childbearing potential (defined as <2 years after last menstruation and not surgically sterile).
  • Male participants who are not surgically sterile and for least 4 months after the last dose of study intervention:
  • do not agree to be abstinent for sexual intercourse; or II. do not agree to use a male condom when engaging in sexual activity that allows for passage of ejaculate to another person; or III. donate sperm and do not refrain from donating sperm.
  • Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.
  • History of drug or alcohol abuse in the opinion of the Investigator within 3 years before screening.
  • Evidence of any other medical condition (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk for treatment-related complications, as judged by the Investigator.
  • Patients on anticoagulants for whom temporarily stop and start is not an option to obtain biopsies, at the discretion of the investigator and/or per local standard of care.

Trial locations and contacts

1 site in 1 country.

Netherlands1 site

  • Erasmus MC

    Rotterdam, 3015GD

Other trials in Netherlands

About this study

This study is a prospective, open-label, multi-cohort, exploratory phase II clinical trial in patients with either CEACAM5-positive NSQ NSCLC, ER+ breast cancer or gastric cancer. Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). The investigators hypothesize that intratumoral exposure of Tusamitamab ravtansine would be an important factor in determining treatment efficacy. Combining exposure with measurements of tumor PD reactions in a proper PK/PD study is the goal of this study.

Read the detailed description

The investigators hypothesize that intratumoral exposure of Tusamitamab ravtansine would be an important factor in determining treatment efficacy. The rationale to develop an antibody-drug conjugate, like tusamitamab ravtansine, is that it concentrates the active compound (DM4) in cancer tissues, thus confirming this hypothesis in human subjects would be an important step forward. Combining exposure with measurements of tumor PD reactions in a proper PK/PD study is the goal of the study.

Tusamitamab ravtansine is being developed in NSQ NSCLC. The results of the first-in-human study in NSQ NSCLC patients were promising and participants could thus benefit from this treatment. However, other tumor types also express CEACAM5 in tumor cells. The investigators will also recruit metastatic ER+ breast cancer patients and metastatic gastric cancer patients. Hence, there has been more limited data on the safety and efficacy in this patient populations. Addition of these cohorts will help to understand the influence of primary tumor type in determining intratumoral concentrations of Tusamitamab ravtansine.

CEACAM5-positive is defined as IHC ≥2+ in intensity in ≥50% of the tumor cells expressing CEACAM5. Yet, the cut-off value for CEACAM5 expression is arbitrarily selected. A PK/PD relation between CEACAM5 expression and exposure would support the current applied cut-off value for CEACAM5 expression.

Being tested
Tusamitamab ravtansine
Keywords
tusamitamab ravtansine, CEACAM5, Pharmacokinetics
Medical subject headings
Lung Neoplasms, Breast Neoplasms, Stomach Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tusamitamab ravtansineDrug

    Also called SAR408701

    Eligible subjects will receive Tusamitamab ravtansine (100mg/m2 IV Q2W). Subjects without evidence of disease progression or drug related toxicity can continue treatment with Tusamitamab ravtansine (100 mg/m2 IV Q2W) until disease progression, unacceptable toxicity occurs, or the participant's or Investigator's decision to stop the treatment.

Study groups in NCT05703555
Study groupRoleWhat they receive
Tusamitamab ravtansine 100mg/m2ExperimentalTusamitamab ravtansine 100 mg/m2 IV Q2W
Receives: Drug: Tusamitamab ravtansine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. intratumoral DM4 concentration

    Intratumoral DM4 exposure, as measured in a biopsied lesion using a PK assay.

    Measured: approximately 5 weeks, more specific day 3 of cycle 2 (each cycle is 14 days)

Secondary outcomes (16)

  1. Intratumoral tusamitamab ravtansine concentration

    Intratumoral concentrations of Tusamitamab ravtansine and metabolites of DM4: Lys-SPDB-DM4, Me-DM4 using a PK assay

    Measured: approximately 5 weeks, more specific day 3 of cycle 2 (each cycle is 14 days)

  2. Incidence of grade 3 or 4 adverse events

    Incidence of grade 3 or 4 adverse events as assessed by CTCAE version 5.0

    Measured: during treatment (up to 2 years and 12 weeks)

  3. Response to treatment

    Number of participants with either progressive disease, stable disease, partial response or complete response according to RECIST v 1.1

    Measured: every 8 weeks during treatment (up to 2 years and 12 weeks)

  4. CEACAM5 expression

    Change in CEACAM5 expression from baseline as assessed by immunohistochemistry

    Measured: approximately 5 weeks, more specific day 3 of cycle 2 (each cycle is 14 days)

  5. RNA expression levels

    Change from baseline in RNA expression levels as assessed with differential gene-level analysis in DESeq2

    Measured: approximately 5 weeks, more specific day 3 of cycle 2 (each cycle is 14 days)

  6. circulating CEA levels

    Number of patients with elevated levels of circulation CEA

    Measured: every 8 weeks during treatment (up to 2 years and 12 weeks)

  7. tumor genomic features

    Somatic copy number, strucural and nucleotide alterations as assessed by whole genome sequencing

    Measured: baseline

  8. Maximal plasma concentration

    Cmax and its corresponding time (Tmax)

    Measured: baseline and at 7 different time points during treatment (3x cycle 1 day 1, 1x pre-dose cycle 2 day 1, 2x cycle 2 day 2, and 1x pre-dose cycle 4 day 1) (each cycle is 14 days)

  9. AUCinf

    AUCinf - Area under the curve form time of dosing extrapolated to infinity of AUC0-t + Clast/lambda z

    Measured: baseline and at 7 different time points during treatment (3x cycle 1 day 1, 1x pre-dose cycle 2 day 1, 2x cycle 2 day 2, and 1x pre-dose cycle 4 day 1) (each cycle is 14 days)

  10. AUClast

    AUClast - Area under the curve form the time of dosing to the time of the last quantifiable concentration calculated using the linear trapezoidal rule

    Measured: baseline and at 7 different time points during treatment (3x cycle 1 day 1, 1x pre-dose cycle 2 day 1, 2x cycle 2 day 2, and 1x pre-dose cycle 4 day 1) (each cycle is 14 days)

  11. AUCt

    AUCt - Area under the concentration versus time curve

    Measured: baseline and at 7 different time points during treatment (3x cycle 1 day 1, 1x pre-dose cycle 2 day 1, 2x cycle 2 day 2, and 1x pre-dose cycle 4 day 1) (each cycle is 14 days)

  12. Thalf

    Thalf will be calculated as ln(2)/Lambda z

    Measured: baseline and at 7 different time points during treatment (3x cycle 1 day 1, 1x pre-dose cycle 2 day 1, 2x cycle 2 day 2, and 1x pre-dose cycle 4 day 1) (each cycle is 14 days)

  13. systemic tusamitamab ravtansine concentration

    Clearance (Cl)

    Measured: baseline and at 7 different time points during treatment (3x cycle 1 day 1, 1x pre-dose cycle 2 day 1, 2x cycle 2 day 2, and 1x pre-dose cycle 4 day 1) (each cycle is 14 days)

  14. Volume of distribution

    Volume of distribution

    Measured: baseline and at 7 different time points during treatment (3x cycle 1 day 1, 1x pre-dose cycle 2 day 1, 2x cycle 2 day 2, and 1x pre-dose cycle 4 day 1) (each cycle is 14 days)

  15. concentration DM4 metabolites: Lys-SPDB-DM4, Me-Dm4

    concentration of metabolites of DM4 will be described

    Measured: baseline and at 7 different time points during treatment (3x cycle 1 day 1, 1x pre-dose cycle 2 day 1, 2x cycle 2 day 2, and 1x pre-dose cycle 4 day 1) (each cycle is 14 days)

  16. features in tumor micro-environment

    RNA-sequencing to deduce the immune contexture using quanTIseq, tumor infiltrating lymphocyte signatures and related workflows

    Measured: approximately 5 weeks, more specific day 3 of cycle 2 (each cycle is 14 days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jan 2023
  2. Study start16 Feb 2024
  3. Primary completion16 Feb 2024
  4. Study completion16 Feb 2024

Why it stopped: Due to the decision to discontinue the global clinical development program of tusamitamab ravtansine

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
open-label, multi-cohort
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05703555
Sponsor's protocol ID
INTRUSION
Other IDs
2022-003451-34
Acronym
INTRUSION
Status last verified
Feb 2024
First submitted
13 Dec 2022
Last updated
28 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: By means of a publication in a peer-reviewed international journal

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Tusamitamab ravtansine in people with Metastatic Lung Cancer and Metastatic Breast Cancer, run by Erasmus Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 47 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 28 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

intratumoral DM4 concentration (time frame: approximately 5 weeks, more specific day 3 of cycle 2 (each cycle is 14 days)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05703555.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in